Rain Oncology Inc
Change company Symbol lookup
Select an option...
RAIN Rain Oncology Inc
CEIX CONSOL Energy Inc
WDBG Neuro-Hitech Inc
GLRY Inspire Faithward Mid Cap Momentum ETF
WCC Wesco International Inc
TNP-F Tsakos Energy Navigation Ltd
ANEB Anebulo Pharmaceuticals Inc
NCA Nuveen California Municipal Value Fund
SGOL abrdn Physical Gold Shares ETF
GAB-K Gabelli Equity Trust Inc
Go

Health Care : Pharmaceuticals |
Company profile

Rain Oncology Inc., formerly Rain Therapeutics Inc., is a late-stage precision oncology company. The Company is focused on developing therapies that target oncogenic drivers to genetically select patients. The Company’s product candidates include milademetan and RAD52. Its milademetan is an oral small molecule, an inhibitor of mouse double minute 2 (MDM2) is being developed in patients with wildtype tumor protein 53 (p53) cancers that are also exhibiting MDM2 dependence. MDM2 dependence may be occurring either through MDM2 gene amplification, protein overexpression, loss of an MDM2 regulator, or other mechanisms. RAD52 is focused on the DNA Damage Response (DDR) pathway. RAD52 represents a strategy for patients that may exhibit homologous recombination deficiencies (HRD+), or a loss of function, of several pathway constituents, including BRCA1/2, PALB2, or several others in tumor types frequently characterized by these deficiencies.

Postmarket

Last Trade
Delayed
$8.28
-0.17 (-2.01%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$8.45
Day's Change
-0.01 (-0.12%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
8.78
Day's Low
8.36
Volume
(Light)
Volume:
69,771

10-day average volume:
223,522
69,771

Upcoming Events

RAIN's fiscal year ends in December
There are no upcoming events for RAIN

Past Earnings

This page reports .
DateEvent descriptionEarnings per
share actual
Earnings
estimate range
Previous year's
actual
March 9, 2023Q4 2022 Earnings Release-$0.70-$0.67 to -$0.45-$0.68
November 10, 2022Q3 2022 Earnings Release-$0.68-$0.73 to -$0.65-$0.70
August 4, 2022Q2 2022 Earnings Release-$0.66-$0.69 to -$0.60-$0.39
May 4, 2022Q1 2022 Earnings Release-$0.66-$0.73 to -$0.65-$1.93

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

, , , Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.